Suppr超能文献

老年急性髓系白血病(AML)和高危骨髓增生异常综合征(MDS)患者造血干细胞移植(HSCT)中减低强度预处理(RIC)方案的前瞻性可行性分析

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

作者信息

Estey Elihu, de Lima Marcos, Tibes Raoul, Pierce Sherry, Kantarjian Hagop, Champlin Richard, Giralt Sergio

机构信息

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

出版信息

Blood. 2007 Feb 15;109(4):1395-400. doi: 10.1182/blood-2006-05-021907. Epub 2006 Oct 12.

Abstract

To prospectively assess the applicability of reduced-intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT), we wrote a protocol in which all untreated patients 50 years or older with acute myeloid leukemia (AML) and unfavorable cytogenetics would be evaluated during induction for a possible RIC-HSCT in first complete remission (CR1). Ninety-nine of 259 patients entered CR. Fifty-three of the 99 were seen by the Transplant Service with the remainder not seen because of illness, lack/unavailability of siblings, refusal, or, primarily, unclear reasons (21 patients). A donor was identified for 26 patients (21 sibling, 5 unrelated) with RIC-HSCT performed in 14 (13 sibling). Results in consulted patients suggested that 50% or fewer of the 85 patients who did not undergo transplantation were potential transplant candidates. We attempted to find one or more chemotherapy pair-mates for each patient who underwent transplantation based on cytogenetics, age, and a relapse-free survival (RFS) time that was more than or equal to the time from CR1 to RIC-HSCT in the patient who underwent transplantation. Thirty-two of the 39 matches favored (longer RFS) RIC-HSCT and 7, chemotherapy. The probability that the corresponding beta distribution was different than expected (ie, that RIC-HSCT was superior) was 0.99 (P=.004). Results were similar with respect to survival. While RIC-HSCT thus seems of interest, methods are needed to extend its applicability.

摘要

为前瞻性评估减低强度预处理造血干细胞移植(RIC-HSCT)的适用性,我们制定了一项方案,即对所有年龄在50岁及以上、患有急性髓系白血病(AML)且细胞遗传学预后不良的未治疗患者,在诱导缓解期评估其是否有可能在首次完全缓解(CR1)时接受RIC-HSCT。259例患者中有99例进入CR。99例中的53例由移植科会诊,其余患者因疾病、缺乏/没有同胞供者、拒绝,或主要因不明原因(21例患者)而未会诊。为26例患者找到了供者(21例同胞供者,5例无关供者),其中14例(13例同胞供者)接受了RIC-HSCT。会诊患者的结果表明,85例未接受移植的患者中,潜在移植候选者不到50%。我们试图根据细胞遗传学、年龄以及无复发生存期(RFS)时间,为每例接受移植的患者找到一个或多个化疗配对伙伴,该RFS时间应大于或等于接受移植患者从CR1到RIC-HSCT的时间。39例配对中,32例倾向于(RFS更长)RIC-HSCT,7例倾向于化疗。相应的贝塔分布与预期不同(即RIC-HSCT更优)的概率为0.99(P = 0.004)。生存方面的结果相似。因此,虽然RIC-HSCT似乎值得关注,但需要方法来扩大其适用性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验